In response to a growth in demand from China for respiratory treatments, AstraZeneca Australia committed to the expansion of its medicine production capacity.
AstraZeneca engaged our services for the installation of three new manufacturing lines for its Pulmicort Respules™ product (Respules 12, 13 and 14). Following the successful commencement of the initial lines, our team was engaged to deliver a fourth line (Respules 15).
The scope of this project included all building and engineering works associated with the installation of the new lines, as well as all associated support and ancillary spaces over three levels.
Our role included advising on buildability, programme and costing, and providing full Construction Services. This included supervising more than 40 direct trade contracts and 10 specialist equipment installation contracts. It also involved managing and coordinating facility commissioning and validation.
